139 related articles for article (PubMed ID: 35578939)
1. [A Case of Postoperative Pulmonary Metastasis of Breast Cancer with Complete Response by Abemaciclib plus Fulvestrant Therapy].
Higashi T; Ozawa K; Takei S; Takagi S; Yokoyama M; Mase K; Moriya T; Takeshita A; Mizutani M
Gan To Kagaku Ryoho; 2022 May; 49(5):581-583. PubMed ID: 35578939
[TBL] [Abstract][Full Text] [Related]
2. [Locally Advanced Breast Cancer Successfully Treated with Abemaciclib and Fulvestrant-A Case Report].
Matsushita K; Hagihara K; Motoki Y; Sakisaka H; Akiyama Y; Nakaguchi K; Doi S
Gan To Kagaku Ryoho; 2020 Dec; 47(13):2165-2167. PubMed ID: 33468895
[TBL] [Abstract][Full Text] [Related]
3. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
[TBL] [Abstract][Full Text] [Related]
4. [A Case of Palbociclib plus Fulvestrant‒Resistant Metastatic Breast Cancer That Responded to Abemaciclib plus Fulvestrant].
Kudo S; Makino T; Umetsu R; Tanaka T
Gan To Kagaku Ryoho; 2021 Apr; 48(4):519-521. PubMed ID: 33976037
[TBL] [Abstract][Full Text] [Related]
5. [Recurrent Breast Cancer with Bone Metastasis Effectively Treated with Abemaciclib plus Endocrine Therapy-A Case Report].
Adachi K; Nagae J; Kubota H; Suzuki S; Hirano T; Sakurai K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1845-1847. PubMed ID: 38303227
[TBL] [Abstract][Full Text] [Related]
6. [Successful Treatment of Estrogen Receptor Positive, HER2 Negative Breast Cancer with Life-Threatening Multiple Bone Metastases Using the Combination of Fulvestrant and Palbociclib-A Case Report].
Nakamura A; Shigekawa T; Asakawa H; Park K; Baba N
Gan To Kagaku Ryoho; 2021 Oct; 48(10):1251-1254. PubMed ID: 34657057
[TBL] [Abstract][Full Text] [Related]
7. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Frenzel M; Lin Y; Barriga S; Smith IC; Bourayou N; Llombart-Cussac A
J Clin Oncol; 2017 Sep; 35(25):2875-2884. PubMed ID: 28580882
[TBL] [Abstract][Full Text] [Related]
8. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
9. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Conte P; Lu Y; Barriga S; Hurt K; Frenzel M; Johnston S; Llombart-Cussac A
JAMA Oncol; 2020 Jan; 6(1):116-124. PubMed ID: 31563959
[TBL] [Abstract][Full Text] [Related]
11. [A Case of Hormone Receptor‒Positive HER2‒Negative Advanced/Recurrent Breast Cancer with 1.5 Years Withdrawal Period of Palbociclib Showed a Good Response Treated by Abemaciclib and Fulvestrant].
Ishiguro A; Tanimoto A; Ito K; Ohigashi A; Kato H; Abe M; Kubota R; Chiba R; Matsunami O; Narita Y
Gan To Kagaku Ryoho; 2021 May; 48(5):697-699. PubMed ID: 34006717
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report.
Ishizuna K; Ninomiya J; Kojima M; Kawashima M; Nozaki M; Yamagishi H; Ueda Y; Oya M
BMC Res Notes; 2013 Jul; 6():254. PubMed ID: 23830415
[TBL] [Abstract][Full Text] [Related]
13. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
Inoue K; Masuda N; Iwata H; Takahashi M; Ito Y; Miyoshi Y; Nakayama T; Mukai H; van der Walt JS; Mori J; Sakaguchi S; Kawaguchi T; Tanizawa Y; Llombart-Cussac A; Sledge GW; Toi M
Breast Cancer; 2021 Sep; 28(5):1038-1050. PubMed ID: 33797023
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
15. [A Case of Pyloric Stenosis Due to Gastric Metastasis of Breast Cancer].
Satoh E; Yatabe Y; Uehira D; Yonekura K; Murakata A; Toyofuku Y; Tanami H; Osanai T; Sugano N; Sakoma T; Maruyama S
Gan To Kagaku Ryoho; 2021 Dec; 48(13):2103-2105. PubMed ID: 35045506
[TBL] [Abstract][Full Text] [Related]
16. [A Long-Surviving Case of Locally Advanced Breast Cancer with Multiple Lung Metastasis].
Satoh E; Innami Y; Uehira D; Yonekura K; Murakata A; Ohinata R; Toyofuku Y; Tanami H; Osanai T; Sugano N; Sakoma T
Gan To Kagaku Ryoho; 2024 Apr; 51(4):427-429. PubMed ID: 38644311
[TBL] [Abstract][Full Text] [Related]
17. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
[TBL] [Abstract][Full Text] [Related]
18. [A Case of Triple Negative Breast Cancer with Successful Control of Recurrent Disease Activity for More than Ten Years].
Yabe N; Watanuki R; Harada Y; Kondo A; Yanagisawa T; Maeda H; Kishi M; Yoshikawa T; Osumi K; Kamiya N; Sotome K; Ishii Y; Jinno H; Ikeda T; Watanabe M
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1759-1761. PubMed ID: 38303198
[TBL] [Abstract][Full Text] [Related]
19. Combining Fulvestrant with Low-Dose Capecitabine is Effective and Tolerable in Woman with Metastatic Breast Cancer.
Nakai M; Takei H; Yanagihara K; Yamashita K; Uchida E
J Nippon Med Sch; 2016; 83(2):81-6. PubMed ID: 27180793
[TBL] [Abstract][Full Text] [Related]
20. [Long-Term Survival of a Patient with Triple-Negative Breast Cancer with Hormone Receptor Status Conversion between Primary and Metastatic Tumors].
Hayashi K; Harao M; Ogihara K; Sasaki Y; Nishida S; Shiba S; Sakuragi M; Kitayama J; Sata N
Gan To Kagaku Ryoho; 2022 Jun; 49(6):697-699. PubMed ID: 35799399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
